PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy
IntroductionBispecific antibodies (BsAbs) can simultaneously target two epitopes of different antigenic targets, bringing possibilities for diversity in antibody drug design and are promising tools for the treatment of cancers and other diseases. T-cel…